Stem Cell Company CardioCell Utilizes BioLife Solutions CryoStor® in Phase II Clinical Trial for Heart Failure

Harvested Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) Are Cryopreserved in CryoStor

BOTHELL, Wash., BioLife Solutions, Inc., the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced that CardioCell, a Stemedica Cell Technologies company, recently published details of its phase II heart failure clinical trial in the Journal of Cardiovascular Medicine.  In the article, titled, Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy, the use of BioLife's clinical grade CryoStor freeze media was disclosed. Details of the study can be found here: A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure.

Over the last several years, adoption of BioLife's biopreservation media products including CryoStor andHypoThermosol in the developing and high growth regenerative medicine market has increased significantly due to the products' ability to extend stability and improve viability and functional recovery of starting material and manufactured cell products.

Mike Rice, BioLife's President & CEO, remarked, "We are very proud to support CardioCell and Stemedica in their quest to commercialize potentially life saving cell based therapies for heart failure patients and other indications.  HypoThermosol and CryoStor are now embedded in over 200 pre-clinical validations and clinical trials of numerous cell based products and therapies.  With this critical mass of regenerative medicine customer clinical trials, and our biologistex™ cloud based cold chain management service that we are just rolling out, we have tremendous opportunities to positively impact the manufacturing and delivery logistics of biologic based medicine and to create significant value for our shareholders."

Source: BioLife Solutions